Previously, in patient samples, we demonstrated a loss of SYK mRNA in normal tissue adjacent to breast cancer, and further decreases in ductal carcinoma in situ (DCIS) and intraductal carcinoma (IDC) compared with normal or benign tissues where no cancer was detected [4]. This evidence concerns the gene SYK and ductal breast carcinoma in situ.